Back to School: How biopharma can reboot drug development. Access exclusive analysis here

As promised, DNXX pulls the plug

The costs of developing recombinant hemoglobin are giving at least some investors and companies pause.

DNX Corp. last week said it is dropping its program for developing a blood substitute from transgenic pigs, after having announced earlier that it wouldn't continue the program without a partner. "We set up some

Read the full 509 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers